country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-189695

Copy Link Print Information

URAT1-IN-18

URAT1-IN-18 is an orally effective URAT1 inhibitor. URAT1-IN-18 inhibits URAT1-mediated urate transport and renal urate reabsorption. URAT1-IN-18 exhibits low cytotoxicity in vitro, with less apoptosis and loss of mitochondrial membrane potential. URAT1-IN-18 shows moderate metabolic stability in rat liver microsomes. URAT1-IN-18 reduces serum uric acid levels in a hyperuricemia mouse model, protects renal tubular structure, and has good biosafety. URAT1-IN-18 can be used for research related to hyperuricemia.

For research use only. We do not sell to patients.

CAS No.: 3133114-23-2
Formula: C₁₄H₇Cl₂NO₃S
Molecular Weight:340.18

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

URAT1-IN-18 Chemical Structure

CAS No.: 3133114-23-2

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	IC50	111.4 μM	Cytotoxicity against human embryonic kidney 293 T cells assessed as viability reduction after 72 hrs by CCK-8 assay. Cytotoxicity against human embryonic kidney 293 T cells assessed as viability reduction after 72 hrs by CCK-8 assay.	42743610
HepG2	IC50	319.8 μM	Cytotoxicity against human hepatocellular carcinoma HepG2 cells assessed as viability reduction after 72 hrs by CCK-8 assay. Cytotoxicity against human hepatocellular carcinoma HepG2 cells assessed as viability reduction after 72 hrs by CCK-8 assay.	42743610

In Vitro

Renal RegulationAnti-cancerApoptosisMitochondrial FunctionOthers

Renal Regulation

URAT1-IN-18 (Compound L22) (8 min) inhibits hURAT1-mediated urate uptake in 293 T cells with an IC₅₀ of 220 nM^[1].

Anti-cancer

URAT1-IN-18 (0-500 μM; 72 h) showed low cytotoxicity in 293 T and HepG2 cells, with CCK-8 IC₅₀ values of 111.4 μM and 319.8 μM, respectively^[1].

Apoptosis

Anti-cancer

URAT1-IN-18 (100 μM; 24 h) induced less apoptosis in 293 T and HepG2 cells^[1].

Mitochondrial Function

URAT1-IN-18 (100 μM; 24 h) caused slight loss of mitochondrial membrane potential in 293 T and HepG2 cells, at 6.67% and 3.41%, respectively^[1].

Others

URAT1-IN-18 (0-60 min) exhibited moderate metabolic stability in rat liver microsomes, with 31.5% remaining after 60 min and a half-life of 36.5 min^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

human embryonic kidney 293 T cells and human hepatocellular carcinoma HepG2 cells
Concentration:

100 μM
Incubation Time:

24 h
Result:

Induced minimal apoptosis in 293 T cells (1.3%) and HepG2 cells (3.8%).

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	AUC_0-∞	CL	MRT_0-t	MRT_0-∞	F
Rat^[1]	2 mg/kg	i.v.	0.75 h	0.0833 h	6900 ng/mL	1012 ng·h/mL	1026 ng·h/mL	2053 mL/h/kg	0.226 h	0.285 h	/
Rat^[1]	10 mg/kg	p.o.	1.69 h	0.5 h	363 ng/mL	893 ng·h/mL	1004 ng·h/mL	10,022 mL/h/kg	2.57 h	3.59 h	17.6 %

In Vivo

Nucleotide Metabolism

URAT1-IN-18 (Compound L22) (2 mg/kg; p.o.; once daily; for 5 consecutive days) reduced serum uric acid in an acute hyperuricemia Kunming mouse model^[1].
URAT1-IN-18 (2 mg/kg; p.o.; once daily; days 1-14 and days 15-19) reduced serum uric acid in a chronic hyperuricemia Kunming mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Kunming (male; 3-week-old; 19-21 g)^[1]
Dosage:

2 mg/kg
Administration:

p.o. (gavage); once daily; for 5 consecutive days
Result:

Reduced serum uric acid to 613.7 μM, corresponding to a 48.1% decrease rate.

Animal Model:

Kunming (male; 3-week-old; 19-21 g)^[1]
Dosage:

2 mg/kg
Administration:

p.o. (gavage); once daily; days 1-14 and days 15-19
Result:

Reduced serum uric acid to 421 μM, corresponding to a 64.1% decrease rate.
The renal tubule structures were more intact and arranged more regularly.

Related Protocols :

Chemical Information

CAS No. 3133114-23-2
Molecular Weight 340.18
Formula C₁₄H₇Cl₂NO₃S
SMILES

O=C1SC2=CC=CC=C2N1C(C3=CC(Cl)=C(O)C(Cl)=C3)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Liu W, et al. Design, synthesis, and biological evaluation of non-conjugated Biaryl amide URAT1 inhibitors as potent Uricosuric agents. Bioorganic chemistry. 2026 Sep 11;182:110512. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote